Indeed, a preclinical study showed that the PARPi talazoparib exquisitely synergized with guadecitabine, proving to be an effective combination therapy to treat breast and ovarian cancers irrespective of their BRCA1/2 status. Here, BRCA1 is linked to ovarian carcinoma.